The DOI matches its Crossref record.
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
Abstract
BACKGROUND AND OBJECTIVE: A phase III double-blind, placebo-controlled clinical trial demonstrated that interferon beta-1a (IFN beta-1a) (Avonex, Biogen) significantly delayed progression of disability in relapsing MS patients. The primary clinical outcome was time from study entry until disability progression, defined as > or = 1.0 point worsening from baseline Kurtzke Expanded Disability Status Scale (EDSS) score persisting for at least two consecutive scheduled visits separated by 6 months. The objective of this study was to examine the magnitude of benefit on EDSS and its clinical significance. METHODS: Post hoc analyses related to disability outcomes using data collected during the double-blind, placebo-controlled phase III clinical trial. RESULTS: (1) Clinical efficacy related to disability did not depend on the definition of disability progression. A significant benefit in favor of IFN beta-1a was observed when > or = 2.0 point worsening from baseline EDSS was required or when worsening was required to persist for > or = 1.0 year. (2) Placebo recipients who reached the primary clinical outcome worsened by a larger amount from baseline EDSS than did IFN beta-1a recipients who reached the primary study outcome. (3) Significantly fewer IFN beta-1a recipients progressed to EDSS milestones of 4.0 (relatively severe impairment) or 6.0 (unilateral assistance needed to walk). (4) Cox proportional hazards models demonstrated that the only baseline characteristic strongly correlated with longer time to disability progression was IFN beta-1a treatment. CONCLUSIONS: The primary clinical outcome for the IFN beta-1a clinical trial underestimated clinical benefits of treatment. Results in this report demonstrate that IFN beta-1a treatment is associated with robust, clinically important beneficial effects on disability progression in relapsing MS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Treatment of Multiple Sclerosis: A Review
Hauser, S. L., & Cree, B. A. C. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.05.049 · Cited by 969
Demyelination: The Role of Reactive Oxygen and Nitrogen Species
Smith, K. J., Kapoor, R., & Felts, P. A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00212.x · Cited by 600
Kremenchutzky, M., Rice, G. P. A., Baskerville, J., Wingerchuk, D. M., & Ebers, G. C. (2006) · Brain · doi:10.1093/brain/awh721 · Cited by 447
Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14541-2 · Cited by 383
Cytokine Effects on Glutamate Uptake by Human Astrocytes
Hu, S., Sheng, W. S., Ehrlich, L. C., Peterson, P. K., & Chao, C. C. (2000) · Neuroimmunomodulation · doi:10.1159/000026433 · Cited by 376
A longitudinal study of brain atrophy in relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M. K., Rudick, R. A., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., et al. (1999) · Neurology · doi:10.1212/wnl.53.1.139 · Cited by 340
Self-citationMagnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Self-citationCladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial
Rice, G. P. A., Filippi, M., Comi, G., & for the Cladribine Clinical Study Group and for the Cladribine MRI Study Group* (2000) · Neurology · doi:10.1212/wnl.54.5.1145 · Cited by 325
Interferons in relapsing remitting multiple sclerosis: a systematic review
Filippini, G., Munari, L., Incorvaia, B., Ebers, G. C., Polman, C., D'Amico, R., & Rice, G. P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12512-3 · Cited by 302
Progress in determining the causes and treatment of multiple sclerosis
Noseworthy, J. H. (1999) · Nature · doi:10.1038/399a040 · Cited by 278
Bush, D. R., Zang, L., Belov, A. M., Ivanov, A. R., & Karger, B. L. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03218 · Cited by 92
Metadata
- Authors
- Rudick, R. A., Goodkin, D. E., Jacobs, L. D., Cookfair, D. L., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Granger, C. V., Simon, J. H., Alam, J. J., Simonian, N. A., Campion, M. K., Bartoszak, D. M., Bourdette, D. N., Braiman, J., Brownscheidle, C. M., Coats, M. E., Cohan, S. L., Dougherty, D. S., Kinkel, R. P., Mass, M. K., Munschauer, F. E., Priore, R. L., Pullicino, P. M., Scherokman, B. J., Weistock-Guttman, B., Whitham, R. H., & The Multiple Sclerosis Collaborative Research Group (MSCRG)
- Venue
- Neurology
- Published
- 1997-08
- Volume
- 49
- Issue
- 2
- Pages
- 358-363
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2112246282
- Cited by
- 232
- References
- 0
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.